These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8898993)

  • 1. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens.
    Tennant RW; Spalding J; French JE
    Mutat Res; 1996 Sep; 365(1-3):119-27. PubMed ID: 8898993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformation of BALB/c-3T3 cells: V. Transformation responses of 168 chemicals compared with mutagenicity in Salmonella and carcinogenicity in rodent bioassays.
    Matthews EJ; Spalding JW; Tennant RW
    Environ Health Perspect; 1993 Jul; 101 Suppl 2(Suppl 2):347-482. PubMed ID: 8243403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.
    Spalding JW; French JE; Tice RR; Furedi-Machacek M; Haseman JK; Tennant RW
    Toxicol Sci; 1999 Jun; 49(2):241-54. PubMed ID: 10416269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models.
    Tennant RW; French JE; Spalding JW
    Environ Health Perspect; 1995 Oct; 103(10):942-50. PubMed ID: 8529591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tg.AC genetically altered mouse: assay working group overview of available data.
    Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
    Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
    Mitsumori K; Koizumi H; Nomura T; Yamamoto S
    Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays.
    Spalding JW; French JE; Stasiewicz S; Furedi-Machacek M; Conner F; Tice RR; Tennant RW
    Toxicol Sci; 2000 Feb; 53(2):213-23. PubMed ID: 10696769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
    Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
    Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays.
    Tennant RW
    Environ Health Perspect; 1998 Apr; 106 Suppl 2(Suppl 2):473-6. PubMed ID: 9599694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
    Yamamoto S; Urano K; Nomura T
    Toxicol Lett; 1998 Dec; 102-103():473-8. PubMed ID: 10022298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictions for the outcome of rodent carcinogenicity bioassays: identification of trans-species carcinogens and noncarcinogens.
    Tennant RW; Spalding J
    Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):1095-100. PubMed ID: 8933059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
    Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
    Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenic activity of carcinogens detected in transgenic rodent mutagenicity assays at dose levels used in chronic rodent cancer bioassays.
    Schmezer P; Eckert C; Liegibel UM; Zelezny O; Klein RG
    Mutat Res; 1998 Sep; 405(2):193-8. PubMed ID: 9748572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
    Yamamoto S; Urano K; Koizumi H; Wakana S; Hioki K; Mitsumori K; Kurokawa Y; Hayashi Y; Nomura T
    Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):57-69. PubMed ID: 9539005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions.
    Sistare FD; Thompson KL; Honchel R; DeGeorge J
    Int J Toxicol; 2002; 21(1):65-79. PubMed ID: 11936901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of transgenic mouse models in carcinogen identification.
    Pritchard JB; French JE; Davis BJ; Haseman JK
    Environ Health Perspect; 2003 Apr; 111(4):444-54. PubMed ID: 12676597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.